ORIC PHARMACEUTICALS

ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

09 Dec 2021 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

11 Nov 2021 15:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

08 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

04 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

07 Oct 2021 07:55:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

30 Sep 2021 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

21 Sep 2021 05:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

01 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors

16 Aug 2021 15:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

10 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

28 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

02 Jun 2021 15:55:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

26 May 2021 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel

25 May 2021 07:00:03 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

06 May 2021 15:05:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

28 Apr 2021 15:05:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

12 Apr 2021 05:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

23 Mar 2021 15:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

10 Mar 2021 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

02 Mar 2021 05:30:00 By Nasdaq GlobeNewswire